|Bid||0.00 x 800|
|Ask||0.00 x 100|
|Day's Range||71.40 - 74.57|
|52 Week Range||26.54 - 92.18|
|Beta (3Y Monthly)||0.52|
|PE Ratio (TTM)||142.37|
|Earnings Date||Nov 6, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||61.71|
Medtronic (MDT) demonstrated improved performances at CER on growth in all business segments. However, costs continue to escalate.
REDWOOD CITY, Calif. , Nov. 19, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present results from two large studies of the Oncotype DX Breast Recurrence Score ® ...
Three short years ago, Myriad Genetics was the undisputed leader of the genetic testing industry. A persistent competitor just challenged the diagnostic company -- and a second one is nipping at its heels.
The future of genetic medicine — and DNA stocks — is extremely bullish over the long term. But as is normal of any emerging technology, there will be plenty of bumps along the road. The good news is that those bumps will provide many opportunities to buy DNA stocks along the way.
Genomic Health (GHDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q3, driven by solid performances in the United States and internationally.
Genomic Health stock popped Tuesday after the medtech firm reported adjusted earnings of 37 cents a share on $101.3 million in sales. In after-hours trades, Genomic Health stock jumped 3.2%.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 7) Allakos Inc (NASDAQ: ALLK ) BioTelemetry Inc (NASDAQ: ...
REDWOOD CITY, Calif. , Nov. 8, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the 2018 Canaccord Genuity Medical Technologies and Diagnostics Forum in ...
Stock futures rose sharply on election results: Democrats won the House but the GOP held the Senate. Seven leaders were big stock market movers on earnings.
The genetic-testing leader kept up its impressive streak of profitable growth during the third quarter of 2018. It now expects earnings several times higher than previous estimates.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 6) Allakos Inc (NASDAQ: ALLK ) Allogene Therapeutics Inc ...
Genomic Health (GHDX) delivered earnings and revenue surprises of 400.00% and 7.21%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Redwood City, California-based company said it had profit of 32 cents. Earnings, adjusted for non-recurring costs, were 35 cents per share. The results beat Wall Street expectations. ...
Reported $101M in Revenue and Delivered 23 Percent Growth on a Pre-606 Adjusted Revenue Basis Delivered $12M Profit on a GAAP Basis; $13M Profit on a Non-GAAP Basis Achieved 13th Consecutive Quarter of ...
Genomic Health is the IBD Stock Of The Day as the cancer diagnostics firm aims for its third straight quarter of double-digit sales growth.
REDWOOD CITY, Calif. , Oct. 30, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Tuesday, November 6 at 4:30 p.m. Eastern ...
Medicare coverage supports clinical utility of the Oncotype DX AR-V7 Nucleus Detect test, providing 25,000 Medicare patients with coverage SAN DIEGO and REDWOOD CITY, Calif. , Oct. 29, 2018 /PRNewswire/ ...
The findings, presented at the ESMO 2018 Congress in Munich, Germany, demonstrated that the Oncotype DX tests identify patients who will or will not benefit from a specific treatment. Underscoring the growing international impact of the Oncotype DX Breast Recurrence Score® test, two European-based studies involving patients from Ireland, France and Italy demonstrated its impact on treatment decisions for women with node-negative and node-positive breast cancer. Additionally, three prostate cancer studies in the United States demonstrated how the Oncotype DX Genomic Prostate Score® (GPS™) and AR-V7 Nucleus Detect™ tests refine treatment decisions in men with clinically low-intermediate risk or metastatic prostate cancer based on the aggressiveness of their tumor or their resistance to androgen receptor (AR)-targeted drugs.
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
GNC Holdings (GNC) registers strong performance in e-commerce business and International segment. In fact, the company is putting an all-out effort to strengthen its international presence.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...